HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis.

AbstractBACKGROUND:
The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy.
OBJECTIVE:
We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments.
METHODS:
In all, 701 randomly assigned patients self-initiated therapy with famciclovir (1500 mg once [single dose] or 750 mg twice a day for 1 day [single day]) or placebo within 1 hour of onset of the prodromal symptoms of an episode of herpes labialis. Lesion healing was monitored by diaries and frequent clinic visits.
RESULTS:
Median healing times of primary (first to appear) vesicular lesions in the famciclovir single-dose, famciclovir single-day, and placebo groups were 4.4, 4.0, and 6.2 days, respectively. There was no significant difference between the famciclovir regimens. Adverse events in the famciclovir groups were similar to placebo.
LIMITATIONS:
The active arms of this trial were not directly compared to other antiviral regimens.
CONCLUSION:
Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.
AuthorsSpotswood L Spruance, Neil Bodsworth, Harvey Resnick, Marcus Conant, Claude Oeuvray, Joseph Gao, Kamal Hamed
JournalJournal of the American Academy of Dermatology (J Am Acad Dermatol) Vol. 55 Issue 1 Pg. 47-53 (Jul 2006) ISSN: 1097-6787 [Electronic] United States
PMID16781291 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • 2-Aminopurine
  • Famciclovir
Topics
  • 2-Aminopurine (administration & dosage, analogs & derivatives)
  • Administration, Oral
  • Adult
  • Antiviral Agents (administration & dosage)
  • Double-Blind Method
  • Famciclovir
  • Female
  • Herpes Labialis (drug therapy)
  • Humans
  • Male
  • Self Administration
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: